Skip to Main Content

After a ‘skinny label’ was used to market a generic version of a pricey brand-name medicine, more consumers gained access to the lower-cost copycat drug and saved on out-of-pockets cost, a new study finds.

In this instance, a generic version of the Gleevec cancer drug became available in 2016. But while the product label noted it could be used to treat a form of leukemia known as CML and other cancers, the generic labeling deliberately excluded language saying it could be used to treat uncommon tumors in the gastrointestinal tract, a condition called GIST.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment